Asia Edition

San Diego biotech Axiom Biosciences announced July 21 it intends to become the first U.S. biotech company to list primarily on the Hong Kong Stock Exchange, targeting a $200 million-plus IPO in 2027. The decision, driven by proximity to Chinese clinical partners and a reformed HKEX biotech framework that has attracted 70-plus listings, is being framed by SCMP and BioSpace as a potential template for other U.S. founders weighing non-U.S. venues.